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Supplemental experimental procedures 
Origin of materials. DNA sequencing services were provided by MICROSYNTH, Balgach, 
Switzerland. Myriocin was from SIGMA (St.Louis, MO), Aureobasidin A from Takara Shuzo Co. 
(Shiga, Japan). PHS and DHS were from Avanti Polar (Alabaster, Alabama). PHS and DHS (stocks = 
2.5mM in methanol), myriocin (stock = 1mg/ml in methanol) and aureobasidin A (stock = 0.5mg/ml in 
ethanol) were added to molten agar before pouring plates. 
Cell labeling, lipid extraction, mild base treatment and thin-layer chromatography. Unless stated, 
metabolic labeling, cell disruption, lipid extraction and analysis were carried out as previously 
described (38). Where indicated, lipids were subjected to mild base treatment using NaOH as 
described (Becker and Lester, 1980, J Bacteriol, 142, 747-54), but incubating 1h at 37°C. Solvent 
systems 55:45:5 or 55:45:10 [chloroform:methanol:0.25%KCl] were used in ascending TLC on silica 
gel plates. Radioactivity was detected and quantified by one- and two-dimensional radioscanning 
(Berthold) and visualized by fluorography or radioimaging using the Bio-Rad Molecular Imager FX.  
GPI remodeling. Preparation and analysis of [3H]myo-inositol labeled GPI anchor lipids were done as 
described (37) with minor modifications. After delipidation proteins were incubated for 15 min at 
60°C instead of 37°C. For octyl-Sepharose chromatography the pH was adjusted to 5.5 instead of 4.5. 
Lipids were mixed with “cold” lipids extracted from 1 A600 unit of cells and analyzed by TLC in 
solvent 55:45:5. 
Mass spectrometry analysis of lipid extracts. Mass spectrometry of lipids was done essentially as 
described (13) with modifications. Exponentially growing cells (A600 of 1-3) were extracted as 
described (41), using procedure IIIB. Aliquots in CHCl3-CH3OH were heated and stirred at 65°C for 1 
min to solubilize M(IP)2C. For detection of lyso-IPCs and ceramides in 4 strains, lipid extracts were 
deacylated using methanolic NaOH and desalted. The indicated amounts were immediately injected 
into a normal phase PVA SIL HPLC column (YMC Europe GmbH, D-46514 Scherbeck, Germany, 1 
x 150 mm) and eluted at 45 l/min. Solvents were the following: A, hexane-isopropanol (98:2); B, 
CHCl3-isopropanol (65:35); C, CH3OH. The program used to change solvent composition over time to 
give ratios A:B:C was as follows: 0 min 12:88:0; 3 min 10:74:16; 4 min 8:61:31; 5 through 16 min 
0:0:100; 18 min 0:100:0; 22 through 29 min 12:88:0. Ions in the effluent were ionized by electrospray 
ionisation with an electrode potential of 3.5 kV and the masses of negative ions were detected by a 
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Bruker Esquire-LC quadrupole ion trap mass spectrometer. Alternatively, we used a Thermo Scientific 
LTQ Orbitrap XL mass spectrometer after flow split (1:100) giving a flow rate of 450 nl/min. Total 
ion counts represent the integration of the particular ion throughout the elution region. Alternatively, 
lipid extracts were analyzed by direct infusion mass analysis using a LTQ Orbitrap XL equipped with 
Triversa NanoMate (Advion Biosciences, Ithaca) as previously described (39). 
 
Supplemental calculation 
The deletion of the 4 ceramide synthases affects ceramide incorporation into GPI anchors less 
severely than IPC biosynthesis. 
We estimate that the amount of base resistant GPI anchors made is reduced only by about 2 fold in 4 
cells whereas the amounts of IPCs and MIPCs is reduced 20 fold. The argument goes as follows: In 
Fig. 3A we see that of the 80 μCi [3H]inositol added to cells, W4.SLC1-1 incorporated 45 μCi, 
W4.LAC1 cells 33 μCi into free lipids. It should be noted that the W4.LAC1 cells carry LAC1 and 
LAG1 on a single plasmid so that with regard to acyl-CoA dependent ceramide synthases they can be 
considered to be normal and serve as a control. We calculate from cpm found in GPI anchors (Fig. 3) 
that GPI-associated inositol represents 0.34% of total inositol-containing free lipids in W4.SLC1-1, 
0.76% in W4.LAC1. The fraction of ceramide containing GPIs is 41 and 45%, respectively, so that 
the ceramide-containing GPIs represent 0.168% (0.41 x 0.34%) and 0.342% (0.45 x 0.76%) of 
inositolphospholipids in W4.SLC1-1 and W4.LAC1, respectively. We conclude that the synthesis 
of ceramide containing GPI anchors in W4.SLC1-1 is 49.1% of the one in W4.LAC1. Quantitation 
of free [3H]IPCs plus [3H]MIPCs in the same type of lipid extracts of [3H]inositol-labeled cells shows 
that W4.SLC1-1 cells contain 0.91 – 1.1% of incorporated radioactivity in these free sphingolipids, 
in comparison to 13.5 or 26.9 % in corresponding wt cells (supplemental Table SV). Thus, by 
metabolic labeling, loss of ceramide synthases brings IPCs down 15 to 25 fold whereas ceramide 
containing GPI anchors are down 2 fold. Also the direct comparison shows that in wt cells, IPC in GPI 
anchors account for 1.25% of total IPCs (0.342%/[26.91% + 0.342%]), whereas in the 4 mutant the 
percentage is 13.2% (0.168%/[1.1 + 0.168%]).  
 
Supplemental Figure legends 
Fig. S1. Exogenous water-soluble ceramides cannot rescue growth of 4.SLC1-1 on complete 
synthetic media. Ten fold dilutions of W4.LAC1 and Y4.LAG1 cells were plated onto SDaaUAI 
with or without 0.5 mM hexanoyl-DHS either in the presence or absence of FOA. Plates were 
incubated at 30 °C. 
   
 - 3 - 
Fig. S2. Media requirements of 4 cells. Cells were plated either on LM or on synthetic complete 
medium at 30°C. 
Fig. S3. Systematic analysis of gene deletions in 4.SLC1-1 strains. Gene deletions were verified 
by PCR in 4 and control strains. Arrows in upper parts of each panel indicate the position and 
direction of the primers. “F” is used for sense-strand primers, “R” for anti-sense primers. Primer 
sequences are available in Table SIII. For each gene deletion 3 or 4 PCR reactions were performed 
using different combinations of primers. Products were migrated on 1%-agarose gel and revealed 
using ethidium bromide. A, checking the replacement of LAG1 by TRP1. B, checking the replacement 
of LAC1 by LEU2. C, checking the replacement of YPC1 by KanMX. D, checking the replacement of 
YDC1 by NatMX. E, checking for the presence of pBM150-LAG1 or pBM150-LAC1-LAG1. F, 
checking for the presence of the conserved TLC motif found in all acyl-CoA dependent ceramide 
synthases (8). Results of PCRs are shown under the corresponding schemes. The PCR using primers 
F14/R15 in panel F amplified an unexpected 800 base pair fragment. The fragment was sequenced and 
corresponds to a fragment of YNL152w.  
Fig. S4. No anomalous ceramides are present in GPI anchors of 4 cells. Panels show experiments 
of the same kind as shown in Fig. 3.  
A, when preparing anchor lipids, the bulk of GPI anchor peptides requires 50% propanol to elute from 
the octyl-sepharose column used during purification. Here the more polar anchor peptides already 
eluting at 25% propanol from octyl-sepharose were analyzed in the same experiment as shown in Fig. 
3. Samples in lanes 2 and 9 were already run in Fig. 3, lanes 2 and 8. Note that, due to the incomplete 
removal of detergent, the mobility of all anchor lipids obtained from 25% propanol fraction is lower 
than the mobility of the same lipids obtained from the 50% propanol fraction. An aliquot of the free 
lipids is shown in lane 1.  
Result: 4.SLC1-1 cells do not make any abnormal, more polar GPI anchor lipids. Note that small 
amounts of lyso-PI containing anchors (marked with asterisk) are not abnormal, since lyso-GPI 
anchors are normal intermediates during anchor lipid remodeling (Fig. 1C) and are also seen in wt 
cells (lane 8). (Some polar lipids are seen in lcb1 SLC1-1 cells (lane 7), but it was not tested if they 
are anchor lipids and if they are mild base resistant.)  
B, cells were precultured in LM and labeled in SDaaUA with 100 Ci of [3H]inositol for 120 min at 
30 °C. The released anchor lipids (A) and a comparable amount of free lipids (F) were divided into 
two aliquots, one of which was deacylated using monomethylamine (MMA). The total amount or 
radioactivity in the free lipid extracts is indicated at the bottom (Ci F). Lane 10 contains anchor 
peptides not treated with nitrous acid.  
C, anchor lipids of 4.SLC1-1 cells are compared to the normal profiles found in YPK9 wt cells and 
plc1 and pgc1 cells. Lane 1 contains an aliquot of the lipid extract of [3H]inositol-labeled wt cells, 
lane 8 contains anchor peptides not treated with nitrous acid.  
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Result: GPI anchors with apparently normal TLC mobility are also made in Y4.SLC1-1 cells, as in 
W4.SLC1-1 cells, and also in this strain the amount of ceramide-containing anchors was comparable 
to the one in wt cells.  
YPK9.4 cells can be maintained alive by Lass5, a mammalian LAG1 homologue and ceramide 
synthase, which mainly uses C16:0 and C18:0 fatty acids. As reported before, in such 4.Lass5 cells, 
the free IPCs mainly contain C16 and C18 fatty acids and migrate aberrantly on TLC, while GPI 
anchors contain IPC-3 and IPC-4 having the same mobility as in wt cells, and can be assumed to 
contain C26:0 and C24:0 (29). This is reproduced here in lane 3. In this particular instance it is 
conceivable that the ceramides used for GPI anchoring are also made by the unknown ceramide 
synthesis pathway but it cannot be excluded that they are made by Lass5, which may not be entirely 
specific for C16:0 and C18:0 fatty acids. In contrast, the origin of ceramides in GPI anchors of 
4.SLC1-1 cells cannot be traced to any known ceramide synthase.  
Fig. S5. Synthesis of mild base resistant inositides in 4 cells is reduced by myriocin and AbA. In 
parallel with the experiment shown in Fig. 4B, we also tested the ability of drugs to inhibit 
biosynthesis of anomalous inositolphosphorylsphingolipids in Y4.SLC1-1 (FBY2219) and, as a 
control, W303.SLC1-1 (FBY2192), i.e. wt cells containing SLC1-1. Cells were grown in LM, washed 
2x with SDaaUA and resuspended in the same. After preincubation for 10 min with inhibitors 
(40g/ml of myriocin or 2g/ml of AbA) cells were labeled by addition of 10 Ci of [3H]inositol in 
presence of the same drugs and incubation at 30°C for 2 hours. Aliquots containing the indicated 
amounts of radioactivity (Ci) were either deacylated by NaOH treatment (+) or left untreated (-), 
desalted and analyzed by TLC in solvent 55:45:10 and fluorography. Residual IPCs and MIPCs in 4 
cells are marked by crosses (+), lipid a is indicated with an asterisk (*). Residual PI indicates that mild 
base hydrolysis was not complete in some lanes. 
Fig. S6. Lipid profiling of 4 cells. A, four different 4 cells  were grown in LM at 30°C. Lipids 
were extracted, deacylated and aliquots of 0.1 A600 units were analyzed by LC-ESI-MS on an ion trap 
mass spectrometer. Ion counts corresponding to lyso-IPCs are plotted. While there was no internal 
standard to allow direct comparison of the quantities of lyso-IPCs in these four strains, it is apparent 
that they all display a high ratio of PHS20-containing over PHS18-containing species. B, W303.4 
(FBY958) cells were grown to exponential phase in LM, the various wt strains and an elo3 strain 
were grown in ordinary complete synthetic media. Lipids were extracted using ClCH3-CH3OH (2:1) 
and were analyzed by ESI-MS in positive and negative ion mode on a QSTAR spectrometer as 
described (39). For each strain, the sum of all positive ions corresponding to known lipid species (9 
different lipid classes) was set to 100% and the intensities of all ions corresponding to LCBs were 
expressed as a percentage thereof. Similarly, the sum of all negative ions corresponding to known lipid 
species (17 different lipid classes) were set to 100% and the intensities for all known species of 
phosphatidylserine (PS), lyso-IPCs and LCB-phosphates (LCB-P) were expressed as a percentage 
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thereof. The plot only shows those lipid species, which were significantly under- or overrepresented in 
W303.4 cells. It appears that 4 cells have very high amounts not only of lyso-IPCs, but also of 
LCBs and LCB-phosphates. 
Fig. S7. Lcb1 SLC1-1 cells do not make mild base resistant inositides. A, aliquots (3Ci) of the 
free lipid extracts of W4.SLC1-1 and lcb1 SLC1-1 cells generated during the analysis of GPI 
anchor lipids in Fig. 3, lanes 2 and 7, respectively, were deacylated by NaOH treatment (+) or mock 
incubated (-). Samples were analyzed by TLC using the solvent 55:45:10. The TLC plate was then 
sprayed with EN3HANCER, placed on a film and exposed for 4 weeks. While several mild base 
resistant lipids are present in W4.SLC1-1, no such lipids are visible in lcb1 SLC1-1 cells. The latter 
only contains a trace of residual PI and some barely migrating glycerol-phospho-[3H]inositol, which 
has not been completely removed during the desalting procedure after mild base hydrolysis. B shows 
the result of an identical experiment except that lcb1 SLC1-1 cells were grown without (lanes 3, 6) or 
with (lanes 2, 5) PHS, and that only 0.2 Ci of untreated lipid extract were spotted (lanes 1 - 3), 
whereas 3 Ci of lipid extract was deacylated to obtain the resistant lipids shown in lanes 4 - 6. 
Fig. S8. 4 cells do not contain DNA other than from S.cerevisiae. DNA from W303.4 and 
W4.SLC1-1 cells was prepared and used as template for low stringency PCR at low temperature with 
primers YPC1-VF1 and YPC1-VR1 (lane 2) or LAG1.VF1  and LAG1.VR1 (lane 3), corresponding to 
the coding sequences of YPC1 and LAG1, respectively. As these genes are deleted in both of the above 
strains, annealing temperatures were 12 or 20 °C lower than required for specific amplification of 
YPC1 and LAG1. The products were separated on agarose and boxed bands were excised and used as 
templates for a further round of PCR amplification. The products of this second PCR were sequenced, 
but only 5 of the 9 bands yielded DNA sequence. Nucleotide blasting with these sequences showed 
that they all originate from S.cerevisiae. 
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Supplemental Tables 
Table SI. Yeast Saccharomyces cerevisiae strains  
Strains Genotype Reference 
YPK9 
 
MATa ade2-101
ochre
 his3-200 leu2-1 lys2-
801
amber
 trp1-63 ura3-52 
(26) 
Y2D.LAC1 
(913) 
Same as YPK9, but lac1::LEU2 lag1::TRP1 containing 
pBM150-LAC1 
(26) 
Y4.LAG1 
(FBY2171) 
As YPK9 but lac1::LEU2 lag1::TRP1 ydc1::natMX 
ypc1::kanMX4 containing pBM150-LAG1 
(29) 
Y4.mSLC1-1/LAG1 
(FBY2174) 
As Y4.LAG1but also containing pBF27 This study 
Y4.mSLC1/LAG1 
(FBY2176) 
As Y4.LAG1 but also containing pBF26 This study 
Y4.mSLC1-1 
FBY2187 
As YPK9 but lag1::TRP1, lac1::LEU2 ydc1::natMX 
ypc1::kanMX4 containing pBF27 
This study 
Y4.SLC1-1 (FBY2219) As YPK9 but lag1::TRP1, lac1::LEU2 ydc1::natMX 
ypc1::kanMX4 containing pBF212 
This study 
Y4.SLC1-1a (FBY945) As Y4.SLC1-1, but ypc1::kanMX4::ADE2 This study 
Y4.LAG1a (FBY1183) As Y4.LAG1 but lac1::ADE2 This study 
Y4.LAG1/AUR1 
(FBY988) 
As Y4.LAG1a but also harboring pYC272-AUR1-
LEU2 
This study 
Y4.AUR1 
(FBY992) 
As YPK9 but lac1::ADE2 lag1::TRP1 ydc1::natMX 
ypc1::kanMX4 harboring pYC272-AUR1-LEU2 
This study 
Y4.Lass5a = 4.Lass5-
ADE2 (FBY947) 
As YPK9 but lag1::TRP1 lac1::LEU2 ydc1::natMX 
ypc1::KanMX4::ADE2 containing p413MET-Lass5 
(29) 
W303-1A MATa can1-100 ade2-1 his3-11,15 leu2-3,112 trp1-1 
ura3-1 
(26) 
W303-1B MATa can1-100 ade2-1 his3-11,15 leu2-3,112 trp1-1 
ura3-1 
(26) 
W4.LAC1 
(FBY2169) 
As W303-1A but lac1::LEU2 lag1::TRP1 
ydc1::natMX ypc1::kanMX4 containing pBM150-
LAC1-LAG1  
This study 
W4.mSLC1-1/LAG1 
(FBY2178) 
As W4.LAC1 but also containing pBF27  This study 
W4.mSLC1/LAG1 
(FBY2180) 
As W4.LAC1 but also containing pBF26 This study 
W4.mSLC1-1 
FBY2189 
As W303-1A but lac1::LEU2 lag1::TRP1 
ydc1::natMX ypc1::kanMX4 containing pBF27 
This study 
W4.SLC1-1 
(FBY2220) 
As W3031A but lac1::LEU2 lag1::TRP1 ydc1::natMX 
ypc1::kanMX4 containing pBF212  
This study 
W4.SLC1-1a 
(FBY943) 
As W4.SLC1-1 but ypc1::kanMX::ADE2 This study 
W4.SLC1-1/UBI4 
(FBY1201) 
As W4.SLC1-1 but containing also YEp352-UBI4 This study 
W303.4 
(FBY958) 
As W303-1A but lac1::LEU2 lag1::TRP1 
ydc1::natMX ypc1::kanMX4 
(13) 
W303.4 
(FBY958-Lnew) 
As W303-1A but lac1::LEU2 lag1::TRP1 
ydc1::natMX ypc1::kanMX4 (grown for several weeks 
in continuous liquid culture)  
This study 
W303.mSLC1 As W303-1B but containing pBF26  This study 
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(FBY2185) 
W303.SLC1-1 
(FBY2192) 
As W303-1B but containing pBF212 This study 
SJ21R ura3-52 leu2-3,112 ade1  K. Athenstaedt 
lcb1 SLC1-1 
(4R3-17C) 
As SJ21R but lcb1::URA3 SLC1-1 MEL1 R. Dickson 
pmi40 (C4) MATa leu2-3,112 ura3-52 pmi 40ts Sipos et al.** 
pmi40 lcb1 SLC1-1 
(FBY952) 
lcb1 SLC1-1 pmi40ts This study 
lcb1-100 MATa end8-1 leu2 ura3 his4 bar1 R. Schneiter 
(FBY999)* csg1::kanMX4 csh1::kanMX4 his31 leu20 ura30 
containing pBF26 
This study 
(FBY9100)* CSG1 csh1::kanMX4 his31 leu20 ura30 
containing pBF26 
This study 
(FBY9101)* csg1::kanMX4 CSH1 his31 leu20 ura30 
containing pBF26 
This study 
(FBY9102)* CSG1 CSH1 his31 leu20 ura30 containing pBF26 This study 
(FBY9103)* CSG1 CSH1 his31 leu20 ura30 containing pBF27 This study 
(FBY9104)* csg1::kanMX4 CSH1 his31 leu20 ura30 
containing pBF27 
This study 
(FBY9105)* csg1::kanMX4 csh1::kanMX4 his31 leu20 ura30 
containing pBF27 
This study 
(FBY9106)* CSG1 csh1::kanMX4 his31 leu20 ura30 
containing pBF27 
This study 
(FBY9107)* CSG1 csh1::kanMX4 his31 leu20 ura30 
containing pBF212 
This study 
(FBY9108)* csg1::kanMX4 CSH1 his31 leu20 ura30 
containing pBF212 
This study 
(FBY9109)* csg1::kanMX4 csh1::kanMX4 his31 leu20 ura30 
containing pBF212 
This study 
(FBY9110)* CSG1 CSH1 his31 leu20 ura30 containing 
pBF212 
This study 
BY4742 MATa his31 leu20 lys20 ura30 EUROSCARF, 
(Frankfurt, GE) 
plc1 BY4742, but plc1::kanMX EUROSCARF 
pgc1 BY4742, but pgc1::kanMX EUROSCARF 
elo3 BY4742, but elo3::kanMX EUROSCARF 
ypc1 ydc1 
(FBY2182) 
Same as BY4742, but ypc1::kanMX4 
ydc1::kanMX4::natMX 
This study 
*FBY999 through 9102 are the four meiotic products of a cross of a BY4742 csg1::kanMX with a 
BY4741 csh1::kanMX, both strains containing pBF26, FBY9103 through 9106 are the four meiotic 
products of a cross of a BY4742 csg1::kanMX with a BY4741 csh1::kanMX, both strains containing 
pBF27, and FBY9107 through 9110 are the four meiotic products of a cross of a BY4742 
csg1::kanMX with a BY4741 csh1::kanMX, both strains containing pBF212.  
**Sipos, G., Puoti, A. and Conzelmann, A. (1994) EMBO J 13, 2789-2796 
 
   
 - 8 - 
Table SII. Plasmids 
pBF26 SLC1 in p423Met25 (2 HIS3 MET25 promoter)  (28) 
pBF27 SLC1-1 in p423Met25 (2 HIS3 MET25 promoter) (28) 
pBF212 SLC1-1 in p413Met25 (CEN ARS HIS3 MET25 
promoter) 
(28) 
pBM150-LAC1-
LAG1 
CEN ARS URA3, contains both, LAC1 and LAG1 under 
GAL1,10 promoter  
M. Jazwinsky 
pBM150-LAG1 CEN ARS URA3, pBM150 having LAG1 behind 
GAL1,10 promoter 
M. Jazwinsky 
pBM150-LAC1 CEN ARS URA3, pBM150 having LAC1 behind 
GAL1,10 promoter 
M. Jazwinsky 
pYC272-AUR1-
LEU2 
LEU2 in YC272 (2 AUR1-C)  This study 
YEp352-UBI4 UBI4 in Yep352 (2 URA3) (53) 
   
 - 9 - 
Table SIII. Oligonucleotide primers  
Name of primer Short name Oligonucleotide sequence 5’-> 3’ 
TSC13XhoI.R1  ttccgctcgagcggccTCAAAATACAAATGGAATCAAG
AA 
TSC13HindIII.F1  ccttcccaagcttcatacaATGCCTATCACCATAAAAAGC
C 
LEU2Not1.F1  ccatgcggccgcAGGCCGTTTCTGACAGAGTAA 
LEU2Not1.R1  atgggcggccgcTCGAGGAGAACTTCTAGTATATC 
LAG1.VF2 F1 TCCGTCAAGACTAATATCGATA 
TRP1.VR2 R1 TGAGTAGTATGTTGCAGTCTTT 
LAG1.VF3 F2 TTAGCGGGAAAAGCAAATTGCA 
LAG1.VR3 R2 CGAGAGCTGGCCAAAGAGG 
LAG1.VF1 F3 GAGTTTCAGGGCCCTTTG 
LAG1.VR1 R3 GCTCTCATCAGAATCACTGTCAC 
LAC1-VF1 F4 CCTCCTTGGCTTGTTGCATCC 
LEU2R R4 ATGGTCTTAAGTTGGCGTACA 
LAC1.VF2 F5 TTGTATGTACCATTCGGATTTATGG 
LAC1-VR1 R5 GATATACTAAAGCAACGCTCAT 
KanMX4-F1 F6 GGATCTTGCCATCCTATGGAACTGC 
LAC1.VR2 R6 GGAGTACTGTCAGTTGGAGTAGTGG 
YPC1-VF2 F7 CCCACTAGTGCGGACGGATT 
YPC1-R5 R7 ACGTTATTTTGCCGCCGACG 
YPC1-VF1 F8 GAGAGTTCTGTCCCCGGCG 
YPC1-VR2 R8 GGTACATGTCCCGAATTAGCTA 
YDC1-VF1 F9 CTGATCGTAGCCATTCGGCTCA 
YPC1-VR1 R9 GATTGATCTTCTACGTATGGGC 
YDC1-KO.F1 F10 GTCCGATAGCGTACGCCAACC 
NatMX4-VR1 R10 GTAAGCCGTGTCGTCAAGAGTGGTAC 
YDC1-VF2 F11 CCAGAAGCCCCGATTGAAGG 
YDC1-KO.R1 R11 GATGGGAGTAACTGCTGCATGTG 
114.F1 F12 TCAGAGCTCATTGAAGTACGGATTAGAAGCCG
CCG 
YDC1-VR2 R12 TTACAATTGGCCCCAGATACTC 
LGA1.R1 R13 TCTTGAACAACCACAAATCA 
SLC1.F1  CCAACTAGTCTAGAATACAATGAGTGTGATAG
GTAGGTTCTTGTATTACTTGAGG 
SLC1.R1  CCACTCGAGAATTCTTAATGCATCTTTTTTACA
GATGAACCTTCGTTATG 
LAG1cm.F1 F13 GCCAAGAAAGGATTACAAG 
LAG1cm.R1 R14 CAGATAGTTTAATGTCTTAGAC 
LAC1cm.F1 F14 AGATCATAACGAGTTGACTTT 
LAC1cm.R1 R15 AATAATTTAGAGTTTTGGAGAA 
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Table SV. Small amounts of mild base resistant lipids are present in 4.SLC1-1 cells 
Experiment 
 
Strain 
 % IPC-MIPC* % abnormal*° 
%mild base 
resistant* 
1 YPK9 13.50 1.36 14.87 
2 Y4.SLC1-1 0.83 1.51 2.33 
1 Y4.mSLC1-1 0.99 1.31 2.30 
1 W303 26.91 2.40 29.31 
2 W4.SLC1-1 0.86 1.27 2.12 
4 W4.SLC1-1 0.75 1.05 1.80 
3 W4.mSLC1-1 1.46 1.77 3.22 
1 W4.mSLC1-1 1.33 2.23 3.56 
 Mean of 4 strains 1.04 1.52 2.55 
 Standard deviation +/- 0.29 +/- 0.42 +/- 0.68 
 
The [3H]inositol-labeled lipids were quantified in 4 independent experiments by Berthold 
radioscanning of TLC plates, experiment 4 corresponding to the lipid extract of the experiment shown 
in Fig. 3, lane 2. Cells were grown to exponential phase and metabolically labeled with [3H]inositol 
during 2 h; between 40 and 70% of added radioactivity was incorporated into lipids. Equal aliquots of 
lipid extracts were treated with mild base or left untreated and run on TLC.  
* The mild base resistant lipids of indicated types detectable after treatment with NaOH are expressed 
as a percentage of labeled lipids present in the extract before mild base treatment.  
° The major abnormal mild base resistant lipid was lyso-IPC. 
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